PD-L1 inhibiting mAb, atezolizumab, in combination with the anti-VEGF antibody bevacizumab, has received FDA approval for unresectable HCC based on the IMbrave150 trial [52]; however, no PD-L1-targeting antibody has been approved as standalone treatment for HCC (Table 1). This evidence concerns the gene CD274 and hepatocellular carcinoma.